{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T23:58:10Z","timestamp":1785455890303,"version":"3.56.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Recurrent focal segmental glomerulosclerosis (rFSGS) is a significant cause of graft failure in pediatric patients. Low-density lipoprotein apheresis (LDL-A) is an FDA-approved treatment for pediatric FSGS, but its efficacy is unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This systematic review and descriptive meta-analysis aimed to determine the efficacy of LDL-A in pediatric kidney transplant recipients with rFSGS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources<\/jats:title>\n                    <jats:p>We performed a comprehensive search in Ovid MEDLINE, Cochrane Central Register of Controlled Trials (CENTRAL), Embase (Elsevier), CINAHL (EBSCO), and Scopus (Elsevier) on May 14th, 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study eligibility criteria<\/jats:title>\n                    <jats:p>Studies deemed eligible to be included were case reports, case series, randomized controlled trials, non-randomized controlled trials, and observational studies that reported patient-level data for subjects less than 18\u00a0years old who were administered any protocol of LDL-A following FSGS recurrence post-kidney transplant, and that provided remission status and urine protein\u2013creatinine ratio (UPCR) ranges or values from at least one follow-up after LDL-A initiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants and interventions<\/jats:title>\n                    <jats:p>From the 8 studies that met the inclusion criteria, there were 25 patients who received LDL-A following rFSGS diagnosis post-transplant who were included for meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study appraisal and synthesis methods<\/jats:title>\n                    <jats:p>\n                      Each study was assessed for selection bias, attrition bias, reporting bias, publication bias, and funding conflicts. The remission status for each patient was determined by the UPCR measured at the latest follow-up reported. Complete remission was defined as UPCR\n                      <jats:inline-formula>\n                        <jats:alternatives>\n                          <jats:tex-math>$$\\le$$<\/jats:tex-math>\n                          <mml:math xmlns:mml=\"http:\/\/www.w3.org\/1998\/Math\/MathML\">\n                            <mml:mo>\u2264<\/mml:mo>\n                          <\/mml:math>\n                        <\/jats:alternatives>\n                      <\/jats:inline-formula>\n                      0.2\u00a0g\/g, partial remission as UPCR between 0.2 and 2.0\u00a0g\/g, and no remission as UPCR\n                      <jats:inline-formula>\n                        <jats:alternatives>\n                          <jats:tex-math>$$\\ge$$<\/jats:tex-math>\n                          <mml:math xmlns:mml=\"http:\/\/www.w3.org\/1998\/Math\/MathML\">\n                            <mml:mo>\u2265<\/mml:mo>\n                          <\/mml:math>\n                        <\/jats:alternatives>\n                      <\/jats:inline-formula>\n                      2.0\u00a0g\/g. For our main outcome, the proportions of patients that achieved complete or partial remission were determined by study, then pooled estimates of effect size were calculated using a random-effects inverse-variance model. As a secondary outcome, the average effects of LDL-A on measures of kidney function were quantified by determining the median across individual changes in serum albumin, serum creatinine, estimated glomerular filtration rate (eGFR), and UPCR. Finally, subgroup analyses comparing remissions between LDL-A protocols were performed using Fisher\u2019s exact test.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The pooled proportion of patients that achieved complete remission or partial remission was 0.36 (95% confidence interval (CI), 0.13\u20130.61) and 0.37 (95% CI, 0.14\u20130.62), respectively, at a median follow-up duration of 8\u00a0months (IQR 6\u201324\u00a0months) after LDL-A initiation. Median serum albumin and eGFR values were increased following LDL-A while UPCR decreased, consistent with clinical improvement. No significant differences in remissions were detected between LDL-A protocols, though the detection of real effects may be limited due to small sample sizes and heterogeneity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Limitations<\/jats:title>\n                    <jats:p>All the included studies have moderate\/high risk of bias due to study type, report type, and sample size. There is substantial variability between LDL-A protocols and previous treatments received by patients, possibly contributing to heterogeneity in outcomes between studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and implications of key findings<\/jats:title>\n                    <jats:p>LDL-A achieved a complete remission rate of 36% (95% CI, 0.13\u20130.61) and a partial remission rate of 37% (95% CI, 0.14\u20130.62). Despite limited cases, LDL-A may be effective for pediatric rFSGS post-kidney transplant, warranting studies on its early use post-transplant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration number<\/jats:title>\n                    <jats:p>PROSPERO (ID CRD42024544869).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00467-025-07143-z","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T07:37:03Z","timestamp":1770795423000},"page":"2849-2861","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Low-density lipoprotein apheresis for recurrent focal segmental glomerulosclerosis in pediatric kidney transplant recipients: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4838-9807","authenticated-orcid":false,"given":"Emily T.","family":"Hayes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4463-9493","authenticated-orcid":false,"given":"Debora","family":"Matossian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7458-3251","authenticated-orcid":false,"given":"Annie B.","family":"Wescott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8836-0881","authenticated-orcid":false,"given":"Priya S.","family":"Verghese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"7143_CR1","doi-asserted-by":"publisher","DOI":"10.1111\/petr.13597","volume":"23","author":"A Chua","year":"2019","unstructured":"Chua A, Cramer C, Moudgil A et al (2019) Kidney transplant practice patterns and outcome benchmarks over 30 years: the 2018 report of the NAPRTCS. Pediatr Transplant 23:e13597. https:\/\/doi.org\/10.1111\/petr.13597","journal-title":"Pediatr Transplant"},{"key":"7143_CR2","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.semnephrol.2005.09.001","volume":"26","author":"N Daskalakis","year":"2006","unstructured":"Daskalakis N, Winn MP (2006) Focal and segmental glomerulosclerosis: varying biologic mechanisms underlie a final histopathologic end point. Semin Nephrol 26:89\u201394. https:\/\/doi.org\/10.1016\/j.semnephrol.2005.09.001","journal-title":"Semin Nephrol"},{"key":"7143_CR3","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/3765608","volume":"2016","author":"E K\u00f6nigshausen","year":"2016","unstructured":"K\u00f6nigshausen E, Sellin L (2016) Circulating permeability factors in primary focal segmental glomerulosclerosis: a review of proposed candidates. Biomed Res Int 2016:3765608. https:\/\/doi.org\/10.1155\/2016\/3765608","journal-title":"Biomed Res Int"},{"key":"7143_CR4","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1097\/01.ASN.0000135051.62500.97","volume":"15","author":"MJ Chun","year":"2004","unstructured":"Chun MJ, Korbet SM, Schwartz MM, Lewis EJ (2004) Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants. J Am Soc Nephrol 15:2169\u20132177. https:\/\/doi.org\/10.1097\/01.ASN.0000135051.62500.97","journal-title":"J Am Soc Nephrol"},{"key":"7143_CR5","doi-asserted-by":"publisher","DOI":"10.5500\/wjt.v6.i1.54","volume":"6","author":"M Messina","year":"2016","unstructured":"Messina M, Gallo E, Mella A et al (2016) Update on the treatment of focal segmental glomerulosclerosis in renal transplantation. World J Transplant 6:54. https:\/\/doi.org\/10.5500\/wjt.v6.i1.54","journal-title":"World J Transplant"},{"key":"7143_CR6","doi-asserted-by":"publisher","DOI":"10.1111\/petr.13154","volume":"22","author":"PS Verghese","year":"2018","unstructured":"Verghese PS, Rheault MN, Jackson S et al (2018) The effect of peri\u2010transplant plasmapheresis in the prevention of recurrent FSGS. Pediatr Transplant 22:e13154. https:\/\/doi.org\/10.1111\/petr.13154","journal-title":"Pediatr Transplant"},{"key":"7143_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fneph.2023.1181076","volume":"3","author":"MN Rheault","year":"2023","unstructured":"Rheault MN, Amaral S, Bock M et al (2023) A randomized controlled trial of preemptive rituximab to prevent recurrent focal segmental glomerulosclerosis post-kidney transplant (PRI-VENT FSGS): protocol and study design. Front Nephrol 3:1181076. https:\/\/doi.org\/10.3389\/fneph.2023.1181076","journal-title":"Front Nephrol"},{"key":"7143_CR8","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1159\/000506277","volume":"49","author":"R Raina","year":"2020","unstructured":"Raina R, Wang J, Sharma A, Chakraborty R (2020) Extracorporeal therapies in the treatment of focal segmental glomerulosclerosis. Blood Purif 49:513\u2013523. https:\/\/doi.org\/10.1159\/000506277","journal-title":"Blood Purif"},{"key":"7143_CR9","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/S0140-6736(82)91513-6","volume":"320","author":"JF Moorhead","year":"1982","unstructured":"Moorhead JF, El-Nahas M, Chan MK, Varghese Z (1982) Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 320:1309\u20131311. https:\/\/doi.org\/10.1016\/S0140-6736(82)91513-6","journal-title":"Lancet"},{"key":"7143_CR10","doi-asserted-by":"publisher","unstructured":"Munn Z, Barker TH, Moola S et al (2019) Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Evid Synth 18:2127\u20132133. https:\/\/doi.org\/10.11124\/JBISRIR-D-19-00099","DOI":"10.11124\/JBISRIR-D-19-00099"},{"key":"7143_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/9781119536604","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"JPT Higgins","year":"2019","unstructured":"Higgins JPT, Thomas J, Chandler J et al (2019) Cochrane handbook for systematic reviews of interventions, 1st ed. Wiley","edition":"1st ed"},{"key":"7143_CR12","doi-asserted-by":"publisher","first-page":"S241","DOI":"10.1016\/j.kint.2024.11.007","volume":"107","author":"J Floege","year":"2025","unstructured":"Floege J, Gibson KL, Vivarelli M et al (2025) KDIGO 2025 clinical practice guideline for the management of nephrotic syndrome in children. Kidney Int 107:S241\u2013S289. https:\/\/doi.org\/10.1016\/j.kint.2024.11.007","journal-title":"Kidney Int"},{"key":"7143_CR13","doi-asserted-by":"publisher","DOI":"10.2196\/64016","volume":"27","author":"JT Fekete","year":"2025","unstructured":"Fekete JT, Gy\u0151rffy B (2025) Metaanalysisonline.com: web-based tool for the rapid meta-analysis of clinical and epidemiological studies. J Med Internet Res 27:e64016. https:\/\/doi.org\/10.2196\/64016","journal-title":"J Med Internet Res"},{"key":"7143_CR14","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/jca.21978","volume":"37","author":"MF Al\u2010mousily","year":"2022","unstructured":"Al\u2010mousily MF, Nicoara O, Selewski DT et al (2022) Low\u2010density lipoprotein apheresis for recurrent focal segmental glomerulosclerosis post renal transplant in pediatric patients. J Clin Apher 37:411\u2013414. https:\/\/doi.org\/10.1002\/jca.21978","journal-title":"J Clin Apher"},{"key":"7143_CR15","doi-asserted-by":"publisher","unstructured":"Mu\u00f1oz M, Lumbreras J, Madrid A et al (2017) P.216 Complete remission of post-transplant recurrence of focal segmental glomerulosclerosis in children with the use of LDL-apheresis therapy: case report. Pediatr Transplant 21:63. https:\/\/doi.org\/10.1111\/petr.12973","DOI":"10.1111\/petr.12973"},{"key":"7143_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2019.00454","volume":"7","author":"R Raina","year":"2019","unstructured":"Raina R, Krishnappa V, Sanchez-Kazi C et al (2019) Dextran-sulfate plasma adsorption lipoprotein apheresis in drug resistant primary focal segmental glomerulosclerosis patients: results from a prospective, multicenter, single-arm intervention study. Front Pediatr 7:454. https:\/\/doi.org\/10.3389\/fped.2019.00454","journal-title":"Front Pediatr"},{"key":"7143_CR17","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1007\/s00467-019-04296-6","volume":"34","author":"L Shah","year":"2019","unstructured":"Shah L, Hooper DK, Okamura D et al (2019) LDL-apheresis-induced remission of focal segmental glomerulosclerosis recurrence in pediatric renal transplant recipients. Pediatr Nephrol 34:2343\u20132350. https:\/\/doi.org\/10.1007\/s00467-019-04296-6","journal-title":"Pediatr Nephrol"},{"key":"7143_CR18","doi-asserted-by":"publisher","unstructured":"McKay A, Di Mola M, Hidalgo J et al (2022) 207.6 LDL apheresis for FSGS recurrence in pediatric kidney transplant recipients: a case series. Pediatr Transplant 26:e14269. https:\/\/doi.org\/10.1111\/petr.14269","DOI":"10.1111\/petr.14269"},{"key":"7143_CR19","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1681\/ASN.20233411S1829c","volume":"34","author":"AJ Kazi","year":"2023","unstructured":"Kazi AJ, Okamura DM, Munshi RP et al (2023) Lipoprotein apheresis in pediatric post-transplant FSGS: SA-PO385. J Am Soc Nephrol 34:829\u2013829. https:\/\/doi.org\/10.1681\/ASN.20233411S1829c","journal-title":"J Am Soc Nephrol"},{"key":"7143_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/petr.14477","volume":"27","author":"J Morey","year":"2023","unstructured":"Morey J, Somers M (2023) Long-term outcomes following LDL apheresis in treatment-refractory recurrent focal segmental glomerulosclerosis. Pediatr Transplant 27:e14477. https:\/\/doi.org\/10.1111\/petr.14477","journal-title":"Pediatr Transplant"},{"key":"7143_CR21","first-page":"786","volume":"160","author":"D Fisher","year":"2021","unstructured":"Fisher D, Borovitz Y, Alfandari H et al (2021) Nephrotic syndrome recurrence post-renal transplantation: 10 years\u2019 experience at Schneider Children\u2019s Medical Center in Israel. Harefuah 160:786\u2013792","journal-title":"Harefuah"},{"key":"7143_CR22","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1002\/jca.21852","volume":"35","author":"M Di Mola","year":"2020","unstructured":"Di Mola M, Licht C, Teoh CW et al (2020) LDL apheresis in the treatment of recurrent focal segmental glomerular sclerosis in a pediatric kidney transplant patient: an initial Canadian experience. J Clin Apher 35:503\u2013565. https:\/\/doi.org\/10.1002\/jca.21852","journal-title":"J Clin Apher"},{"key":"7143_CR23","first-page":"33","volume":"18","author":"Y Jeyakumar","year":"2022","unstructured":"Jeyakumar Y (2022) LDL-A, a novel treatment for recurrence of FSGS in a paediatric renal transplant recipient: a case presentation. Ren Soc Australas J 18:33","journal-title":"Ren Soc Australas J"},{"key":"7143_CR24","first-page":"817","volume":"28","author":"LN Shah","year":"2017","unstructured":"Shah LN, LaRosa CJ, Speckhals J et al (2017) Successful remission of recurrent FSGS following lipid apheresis in renal transplant recipients. J Am Soc Nephrol 28:817","journal-title":"J Am Soc Nephrol"},{"key":"7143_CR25","doi-asserted-by":"crossref","unstructured":"Tran C, Cramp H (2021) 12 Challenges of monitoring and treating recurrence of primary focal segmental glomerulosclerosis after renal transplantation. In: Abstracts. BMJ Publishing Group Ltd, p A6.1-A6","DOI":"10.1136\/bmjpo-2021-RCPCH.11"},{"key":"7143_CR26","unstructured":"Morey J, Somers M (2022) Efficacy of LDL apheresis in therapy refractory recurrent FSGS. American Nephrology Nurses Association"},{"key":"7143_CR27","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1681\/ASN.20233411S1980b","volume":"34","author":"JA Humphrey","year":"2023","unstructured":"Humphrey JA, Rose J, Krallman KA et al (2023) Low-Density Lipoprotein (LDL) Apheresis Removes Atherogenic Mediators in Focal Segmental Glomerulosclerosis: SA-PO906. J Am Soc Nephrol 34:980\u2013980. https:\/\/doi.org\/10.1681\/ASN.20233411S1980b","journal-title":"J Am Soc Nephrol"},{"key":"7143_CR28","doi-asserted-by":"publisher","first-page":"S166","DOI":"10.1016\/j.ekir.2019.05.429","volume":"4","author":"V Krishnappa","year":"2019","unstructured":"Krishnappa V, Sanchez-Kazi C, Quiroga A et al (2019) SUN-034 Liposorber\u00ae LA-15 system for LDL apheresis in drug resistant primary focal segmental glomerulosclerosis patients: interim results from a prospective, multicenter, single-arm intervention study. Kidney Int Rep 4:S166\u2013S167. https:\/\/doi.org\/10.1016\/j.ekir.2019.05.429","journal-title":"Kidney Int Rep"},{"key":"7143_CR29","doi-asserted-by":"publisher","DOI":"10.1111\/petr.13404","volume":"23","author":"JA Morey","year":"2019","unstructured":"Morey JA, Somers MJG (2019) Efficacy of LDL apheresis in therapy refractory recurrent FSGS. Pediatr Transplant 23:e13404. https:\/\/doi.org\/10.1111\/petr.13404","journal-title":"Pediatr Transplant"},{"key":"7143_CR30","doi-asserted-by":"publisher","first-page":"341","DOI":"10.5414\/CNP67341","volume":"67","author":"E Muso","year":"2007","unstructured":"Muso E, Mune M, Yorioka N et al (2007) Beneficial effect of low-density lipoprotein apheresis (LDL-A) on refractory nephrotic syndrome (NS) due to focal glomerulosclerois (FGS). Clin Nephrol 67:341\u2013345. https:\/\/doi.org\/10.5414\/CNP67341","journal-title":"Clin Nephrol"},{"key":"7143_CR31","doi-asserted-by":"publisher","DOI":"10.1080\/0886022X.2023.2176694","volume":"45","author":"J Miao","year":"2023","unstructured":"Miao J, Krisanapan P, Tangpanithandee S et al (2023) Efficacy of extracorporeal plasma therapy for adult native kidney patients with primary FSGS: a systematic review. Ren Fail 45:2176694. https:\/\/doi.org\/10.1080\/0886022X.2023.2176694","journal-title":"Ren Fail"},{"key":"7143_CR32","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s00467-021-05211-8","volume":"37","author":"M Al-mousily","year":"2022","unstructured":"Al-mousily M, Nicoara O, Selewski DT, Twombley K (2022) Liposorber\u00ae la-15 system for LDL apheresis in resistant nephrotic syndrome patients. Pediatr Nephrol 37:585\u2013592. https:\/\/doi.org\/10.1007\/s00467-021-05211-8","journal-title":"Pediatr Nephrol"},{"key":"7143_CR33","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1093\/ndt\/gfp538","volume":"25","author":"C Ponticelli","year":"2010","unstructured":"Ponticelli C (2010) Recurrence of focal segmental glomerular sclerosis (FSGS) after renal transplantation. Nephrol Dial Transplant 25:25\u201331. https:\/\/doi.org\/10.1093\/ndt\/gfp538","journal-title":"Nephrol Dial Transplant"},{"key":"7143_CR34","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1007\/s00467-015-3062-1","volume":"30","author":"R Trachtman","year":"2015","unstructured":"Trachtman R, Sran SS, Trachtman H (2015) Recurrent focal segmental glomerulosclerosis after kidney transplantation. Pediatr Nephrol 30:1793\u20131802. https:\/\/doi.org\/10.1007\/s00467-015-3062-1","journal-title":"Pediatr Nephrol"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-025-07143-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-025-07143-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-025-07143-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T23:05:53Z","timestamp":1785452753000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-025-07143-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["7143"],"URL":"https:\/\/doi.org\/10.1007\/s00467-025-07143-z","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"assertion":[{"value":"1 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article has been revised. The link to the additional supplementary material, including the graphical abstract, was missing and has now been added.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}]}}